Adage Capital Partners Gp, L.L.C. Terns Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,939,000 shares of TERN stock, worth $88.5 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
3,939,000
Previous 1,280,000
207.73%
Holding current value
$88.5 Million
Previous $4.77 Million
527.06%
% of portfolio
0.05%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding TERN
# of Institutions
152Shares Held
90.3MCall Options Held
574KPut Options Held
41.6K-
Soleus Capital Management, L.P. Greenwich, CT8.13MShares$183 Million3.76% of portfolio
-
Morgan Stanley New York, NY7.59MShares$171 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$170 Million1.96% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$168 Million1.8% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$155 Million8.33% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $846M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...